|Bid||63.14 x 3200|
|Ask||63.36 x 1800|
|Day's Range||62.84 - 63.51|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||13.68|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||2.52 (3.99%)|
|1y Target Est||80.80|
The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Thursday's gain felt a little too strong to trust, and sure enough, it didn't last. The S&P 500 fell 0.66% on Friday, leaving it squarely in the middle of equally important support and resistance levels.Source: Shutterstock General Electric (NYSE:GE) was the proverbial problem child. It fell more than 3%, logging its seventh loss in eight sessions as worries about its turnaround resurfaced. Smaller Nektar Therapeutics (NASDAQ:NKTR) posted the decidedly larger loss though, giving up nearly 30% of its value after the company reported a production issue with one of the drugs in a key trial right now.One noteworthy winner … Amgen (NASDAQ:AMGN) rallied 6% on the heels of news it has won a case involving the patent on its Enbrel. There just weren't enough names like Amgen to finish the week on a high note.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Medical Marijuana Stocks to Cure Your Portfolio As the new trading week kicks off, take a closer look at the stock charts of News Corp (NASDAQ:NWSA), Xilinx (NASDAQ:XLNX) and Gilead Sciences (NASDAQ:GILD). They're all positioned for major moves, with just the right nudge. Gilead Sciences (GILD)For the better part of June and July, Gilead Sciences was working on a break above a couple of different resistance levels. Although they were tough, a move above them could mark the beginning of a prolonged move higher. Unfortunately, before that advance had a chance to fully take hold, it petered out in the latter part of July.It may be too soon to give up on GILD stock just yet though. Last week it found support at a (very) familiar spot, and in the meantime we've moved to within reach of what could prove to be a hugely catalytic technical event. * Click to EnlargeThe support is the floor that lines up all the key lows since the end of 2018, marked in white on both stock charts. Gilead shares pushed up and off that floor last week, ending the pullback. * Thanks to June's big jump following a broad rally effort since March, the purple 50-day moving average line is close to crossing above the white 200-day average … a so-called "golden cross" that may spur more buying. * The weekly chart puts things in perspective. The loss since 2015 has been significant. The same weekly chart shows the stock is also on the verge of breaking above a couple different long-term resistance lines driving that downtrend. One is marked in blue, and the other red, tagging all the key highs going back for years. Xilinx (XLNX)Xilinx shares have been fighting a losing battle since July 24, when a budding rally quickly rolled over and turned into a selloff. Broad concerns about trade with China and specific concerns about its relationship with Huawei up-ended the bullish effort.The selloff initially looked manageable. Although the dip wasn't small, shares hinted as if they would find support where they most needed to (and where they did the last time support was found). Thursday's sharp gain largely solidified the bullish backdrop. Friday's big stumble, however, may have cemented more weakness in place. * 10 Internet Stocks Getting Hammered * Click to EnlargeThe line in the sand is the 200-day moving average, plotted in white on both stock charts. XLNX broke that support in a big way on Friday, logging its lowest close in weeks to end the week. * The volume for the past two weeks is problematic for the bulls too. The selling has been on high volume, and the one good day in the midst of the rout -- Thursday -- was clearly on below average volume. * Last week's selling has also pulled Xilinx to within striking distance of a key Fibonacci retracement line near $102. It may not break it with a straight-line move, but it's still vulnerable to such a breakdown. News Corp (NWSA)It was wholly inspired by its fourth-quarter earnings beat. Nonetheless, News Corp shares demonstrated impressive technical strength on Friday, finding support where it ideally would. The big move carried shares to a huge line in the sand as well, and though it didn't push shares past that line, NWSA stock is perfectly positioned to punch through that mark this week. It may just need to peel back a little bit first to get a good running start. * Click to EnlargeThe line in question is right around $13.77, marked in yellow on both stock charts, near where NWSA peaked on Friday as well as in late June. * The rally, however, ultimately started on Wednesday with a hammer-shaped reversal bar that found technical support at the gray 100-day and white 200-day moving average lines. * It would be easy to overlook in the midst of the volatility, but the purple 50-day moving average line moves above the 200-day moving average last month, pointing to a well-established uptrend.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post 3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences appeared first on InvestorPlace.
Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment for patients with HIV-1 that isn't resistant to the integrase inhibitor class of drugs, emtricitabine or tenofovir. Biktarvy received marketing approval from the U.S. Food and Drug Administration and the European Commission in 2018. "Gilead is pleased that people living with HIV in China will now have our newest HIV treatment innovation as a treatment option," said Diana Brainard, Gilead's senior vice president of HIV and emerging viruses, in a statement. Gilead reported earnings last week that beat analysts' expectations. The company's HIV products continue to be a strong base for the company, with second-quarter HIV drug sales growing to $4 billion from $3.7 billion a year ago. Shares of Gilead have gained 3.6% in the year to date through Thursday, while the S&P 500 has gained 17.2%.
Gilead Sciences, Inc. (GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. In China, Biktarvy is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. “Biktarvy offers high rates of efficacy, high barriers to resistance and a demonstrated tolerability profile, underscoring its role as an important new treatment option for a broad range of patients in China,” said Professor Taisheng Li, Director of Infectious Disease Department, Peking Union Medical College Hospital.
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday. Both Gilead's Yescarta and Novartis' Kymriah were approved in 2017 for certain kinds of lymphoma and leukemia.
F/TAF) for the proposed indication of pre-exposure prophylaxis (PrEP) in men and transgender women (TGW) who have sex with men by a vote of 16 to 2. “We appreciate the advisory committee’s thoughtful review and discussion of the data during today’s meeting and look forward to collaborating with FDA to make this potential new prevention option available to people at risk of HIV in the United States,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences.
The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG. CMS, which runs Medicare - the federal government's health plan for Americans 65 and older - said it will cover the U.S. Food and Drug Administration-approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes. The nationwide decision clears up "a lot of confusion" about coverage and will help patients get access to the novel therapies, known as CAR-T, CMS Administrator Seema Verma said during a conference call with reporters on Wednesday.
An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is already approved to treat chronic HIV. When asked to assess the efficacy of Descovy for pre-exposure prophylaxis (PrEP) of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor.